KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Evolent Health (EVH) over the last 11 years, with Q3 2025 value amounting to -$1.1 million.

  • Evolent Health's Gains from Investment Securities fell 64450.0% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year decrease of 6137.04%. This contributed to the annual value of $15.7 million for FY2024, which is 1270.57% down from last year.
  • Per Evolent Health's latest filing, its Gains from Investment Securities stood at -$1.1 million for Q3 2025, which was down 64450.0% from $3.2 million recorded in Q2 2025.
  • Evolent Health's 5-year Gains from Investment Securities high stood at $16.2 million for Q1 2022, and its period low was -$40.9 million during Q4 2022.
  • For the 5-year period, Evolent Health's Gains from Investment Securities averaged around $999588.2, with its median value being $2.7 million (2021).
  • Over the last 5 years, Evolent Health's Gains from Investment Securities had its largest YoY gain of 50342.39% in 2022, and its largest YoY loss of 554444.44% in 2022.
  • Evolent Health's Gains from Investment Securities (Quarter) stood at $9.9 million in 2021, then crashed by 514.21% to -$40.9 million in 2022, then surged by 108.88% to $3.6 million in 2023, then tumbled by 91.5% to $309000.0 in 2024, then tumbled by 452.43% to -$1.1 million in 2025.
  • Its Gains from Investment Securities was -$1.1 million in Q3 2025, compared to $3.2 million in Q2 2025 and $4.6 million in Q1 2025.